Fubotv earnings beat by $0.10, revenue topped estimates
HONG KONG, SHANGHAI & FLORHAM PARK, NJ - HUTCHMED (China) Limited has announced that it will present new clinical data on several of its compounds at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting. The event is scheduled from May 30 to June 3, 2025, in Chicago, USA.
The company will share results from its SACHI China Phase III study, which evaluated the combination of savolitinib and osimertinib in non-small cell lung cancer (NSCLC) patients with specific genetic mutations. The study met its primary endpoint of progression-free survival (PFS) during an interim analysis, leading to a New Drug Application in China that has been accepted and granted priority review.
Additional data from the SAVANNAH Phase II study will also be presented, focusing on the efficacy of the savolitinib and osimertinib combination, especially in patients with brain metastases. The treatment demonstrated improved outcomes compared to savolitinib plus placebo, including reduced central nervous system progression.
The Phase I study of ranosidenib (HMPL-306), a dual-inhibitor targeting mutations in certain enzymes, showed promising results in patients with solid tumors, including gliomas. The compound was well tolerated and demonstrated target inhibition and durable responses, with a disease control rate of 100% in a subset of patients with lower-grade glioma.
HUTCHMED will also present findings from the FRUSICA-1 Phase II study, which assessed the efficacy and safety of fruquintinib in combination with sintilimab in advanced endometrial cancer patients. Results indicated clinically meaningful responses, with comparable outcomes regardless of prior chemotherapy treatments.
Two subgroup analyses from a Phase IV study of fruquintinib involving colorectal cancer patients will be shared, highlighting the safety and potential improved patient outcomes of fruquintinib both as monotherapy and in combination with other anti-cancer treatments.
This information is based on a press release statement from HUTCHMED. The company is an innovative, commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.